Table 2.
Clinical characteristics of patients with suspected PD-L1–related AKI
| Age/race/sex | Cancer type | PD-L1 drug type | Time to AKI, mo | KDIGO AKI stage | Concurrent AIN-associated medications | Concurrent irAE | Kidney biopsy | Steroids | Outcome | Re-challenge |
|---|---|---|---|---|---|---|---|---|---|---|
| 65 WF | SCLC | Atezolizumab | 2 | 1 | PPI | Hypothyroidism | No | No | Transitioned to hospice and died | No |
| 65 WF | RCC | Atezolizumab | 6 | 2 | PPI, NSAIDs, amoxicillin | Colitis | No | Yes | Partial recovery but not to baseline | No |
| 50 WM | Bladder cancer | Atezolizumab | 8 | 1 | Ciprofloxacin | 0 | Yes (AIN) | Yes | No recovery | No |
| 65 WM | Bladder cancer | Atezolizumab | 4 | 3 | Levofloxacin | 0 | No | Yes | Full recovery to baseline | No |
| 55 WF | NSCLC | Durvalumab | 4 | 1 | SAIDs | Immune-related cytopenias | No | No | Full recovery to baseline | Yes Nivolumab 11 mo later without recurrence of AKI |
AIN, acute interstitial nephritis; AKI, acute kidney injury; irAE, immune-related adverse event; NSAIDs, nonsteroidal anti-inflammatory drugs; NSCLC, non–small cell lung cancer; PD-L1, programmed cell death receptor ligand 1; PPI, proton pump inhibitor; RCC, renal cell cancer; SCLC, small cell lung cancer; WF, white female; WM, white male.